<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126537</url>
  </required_header>
  <id_info>
    <org_study_id>2020ZDSYLL041-Y01</org_study_id>
    <nct_id>NCT05126537</nct_id>
  </id_info>
  <brief_title>Co-inhibitory Molecules on Treg and miR-155-5p in Patients With Sepsis</brief_title>
  <official_title>An Observational Study on the Relationship Between Expression of Co-inhibitory Molecules on Treg and miR-155-5p Expression in the Peripheral Blood of Patients With Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      there is high mortality rate of sepsis, 36% in 90-days of sepsis in China, and there is no&#xD;
      effective treatment. Immunosuppression mediated by sepsis is an important cause of death in&#xD;
      patients. Treg cells are important immunomodulatory cell. Treg's over-differentiation is&#xD;
      involved in the development of sepsis induced immunosuppression. In sepsis patients, the&#xD;
      expression of PD-1、CTLA-4 and TIGIT on Treg cell surface increased, and Treg cells with high&#xD;
      expression of co-inhibitory molecules showed stronger immunosuppressive characteristics.&#xD;
      MiR-155-5p is an unencoded RNA transcript from a proto-oncogene B cell integration cluster.&#xD;
      In sepsis, the expression of miR-155 increased in peripheral blood and correlated with the&#xD;
      patient's prognosis. Recent studies have shown that miR-155-5p promotes co-inhibitory&#xD;
      molecules expressed on T cells in LCMV infected animal models. However, the relationship&#xD;
      between the expression of peripheral blood miR-155-5p in sepsis patients and the expression&#xD;
      of co-inhibitory molecules on Treg cell surface is not clear.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. peripheral blood Treg cells and their surface PD-1、CTLA-4 and TIGIT levels in sepsis&#xD;
           patients were measured by flowcytometry. SOFA score、APACHE II score were recorded&#xD;
&#xD;
        2. the level of miR-155-5p were measured by RT-qPCR in patients with sepsis on day 0-1 and&#xD;
           day 3-5, and the correlation between the expression of the co-inhibitory molecules and&#xD;
           miR-155-5p were evaluated&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>28 days</time_frame>
    <description>all patients followed up to 28 days</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>28 Day Mortality</condition>
  <arm_group>
    <arm_group_label>health volunteers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ICU non-sepsis patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>sepsis patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>prospective and observational study with no intervention</description>
    <arm_group_label>ICU non-sepsis patients</arm_group_label>
    <arm_group_label>health volunteers</arm_group_label>
    <arm_group_label>sepsis patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients diagnosed with sepsis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  sepsis 3.0 diagnositic criteria are met. older than 18 years old. total course is less&#xD;
             than 7 days. Informed consent is signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy. patients with active malignant tumors. chronic hepatitis or HIV. patients&#xD;
             under treatment with immunosuppressive drugs (except patients with glucocorticosteroid&#xD;
             prednisone or equivalent dose&lt;10 mg/d per day)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Songqiao Liu</investigator_full_name>
    <investigator_title>Chief</investigator_title>
  </responsible_party>
  <keyword>sepsis immunosuppression Treg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

